Literature DB >> 18425044

BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix.

Riem E Badr1, Ann E Walts, Fai Chung, Shikha Bose.   

Abstract

BD ProEx C (ProEx C) is a recently developed immunocytochemical assay that targets the expression of topoisomerase II-alpha and minichromosome maintenance protein-2, 2 genes shown to be overexpressed in cervical cancers. Recent studies validated this reagent in liquid-based cytology specimens and suggested its usefulness as an adjunct in the diagnosis of challenging cases. Limited information is available on its expression in tissue sections. This study aims to assess ProEx C expression patterns in benign, atypical, and dysplastic lesions of the cervix and to compare these patterns with p16 and Ki67 expression and with the presence of human papilloma virus DNA as determined by in situ hybridization. ProEx C positivity was limited to the basal layers of the epithelium in 75% of benign cervices. In the remaining 25%, staining extended into the lower half of the epithelium particularly in areas of squamous metaplasia and immature squamous metaplasia. In 92% of high-grade dysplasias [cervical intraepithelial neoplasia (CIN) II and III] strong positive staining for ProEx C involved the lower and upper halves of the epithelium. Condylomas and CIN I showed greater variability in staining pattern with ProEx C positivity extending into the upper half of the epithelium in 48% of cases. Statistically significant correlations were noted with presence of human papilloma virus DNA and with p16/Ki67 expression. Atypical squamous metaplasia showed varied staining with 24% being positive. To summarize, ProEx C is a reliable marker for high-grade CIN that can be applied to tissue sections to confirm the diagnosis of high-grade CIN and to triage cases of atypical squamous metaplasia. ProEx C may also have a potential role in triaging patients with low-grade CIN. ProEx C expression patterns are similar to those for p16 and Ki67 with most discrepancies occurring in the CIN I category.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18425044     DOI: 10.1097/PAS.0b013e31815bbb69

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  11 in total

1.  A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.

Authors:  Christina S Kong; Andrew H Beck; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2010-07       Impact factor: 6.394

2.  MOLECULAR MARKERS OF EARLY CERVICAL NEOPLASIA.

Authors:  Alvaro P Pinto; Christopher P Crum; Michelle S Hirsch
Journal:  Diagn Histopathol (Oxf)       Date:  2010-10-01

3.  Claspin as a biomarker of human papillomavirus-related high grade lesions of uterine cervix.

Authors:  Maria Benevolo; Antonio Musio; Amina Vocaturo; Maria Gabriella Donà; Francesca Rollo; Irene Terrenato; Mariantonia Carosi; Edoardo Pescarmona; Giuseppe Vocaturo; Marcella Mottolese
Journal:  J Transl Med       Date:  2012-06-25       Impact factor: 5.531

4.  Cervical intraepithelial neoplasia in pregnancy: Interference of pregnancy status with p16 and Ki-67 protein expression.

Authors:  Andrea Ciavattini; Francesco Sopracordevole; Jacopo Di Giuseppe; Lorenzo Moriconi; Guendalina Lucarini; Francesca Mancioli; Antonio Zizzi; Gaia Goteri
Journal:  Oncol Lett       Date:  2016-11-29       Impact factor: 2.967

5.  p16 is superior to ProEx C in identifying high-grade squamous intraepithelial lesions (HSIL) of the anal canal.

Authors:  Rajeev Bala; Benjamin A Pinsky; Andrew H Beck; Christina S Kong; Mark L Welton; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2013-05       Impact factor: 6.394

6.  Evaluation of ProExC as a prognostic marker in oropharyngeal squamous cell carcinomas.

Authors:  Anne M Mills; Andrew H Beck; Nader Pourmand; Quynh Thu Le; Christina S Kong
Journal:  Am J Surg Pathol       Date:  2012-08       Impact factor: 6.394

7.  Role of protein biomarkers in the detection of high-grade disease in cervical cancer screening programs.

Authors:  Charlotte A Brown; Johnannes Bogers; Shaira Sahebali; Christophe E Depuydt; Frans De Prins; Douglas P Malinowski
Journal:  J Oncol       Date:  2012-02-28       Impact factor: 4.375

8.  Comparative study of ProEx C immunocytochemistry and UroVysion fluorescent in-situ hybridization assays on urine cytology specimens.

Authors:  Sue Chang; Elaine Smith; Mary Levin; Jian-Yu Rao; Neda A Moatamed
Journal:  Cytojournal       Date:  2015-01-22       Impact factor: 2.091

Review 9.  ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review.

Authors:  Gerardo Botti; Maria Gabriella Malzone; Elvira La Mantia; Micaela Montanari; Daniela Vanacore; Sabrina Rossetti; Vincenzo Quagliariello; Carla Cavaliere; Rossella Di Franco; Luigi Castaldo; Gianluca Ametrano; Francesca Cappuccio; Francesco Jacopo Romano; Raffaele Piscitelli; Maria Filomena Pepe; Carmine D'Aniello; Gaetano Facchini
Journal:  Int J Med Sci       Date:  2017-04-21       Impact factor: 3.738

10.  An interaction network driven approach for identifying biomarkers for progressing cervical intraepithelial neoplasia.

Authors:  Shikha Suman; Ashutosh Mishra
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.